Methods The design, baseline characteristics, and primary results of this institutional review
board–approved trial are published. 1, 2 In brief, PARADISE-MI was a double-blind, active …

Background The 5-year mortality rate for patients with chronic HF is similar to that
formanycancers, andthediseaseischaracterizedbyhighratesof… and requirements for …

Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto,
Quebec, Canada) in a nonclinical trial population. This study was conducted to evaluate the …

Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization | Circulation Science
Volunteer Warning signs SearchSearch Advanced Search Donate Circulation logo Hello Guest …

Aim The win ratio can incorporate different types of outcomes and enhance statistical power,
making it a useful method for analysing composite outcomes in cardiovascular trials. The …

In 2015, sacubitril–valsartan was approved in Europe and the United States as a new
therapeutic agent for heart failure with reduced ejection fraction. Approval was based …

Background The combination drug sacubitril/valsartan was reported to be superior to
enalapril in reducing all-cause death, cardiovascular mortality, and heart failure (HF) …

Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in
patients with New York Heart Association class IV heart failure with a reduced ejection …

Aims Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting.
Its safety in real‐life population is not stablished. We compared the initiation of …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …